phosphor stat5 antibody  (Santa Cruz Biotechnology)

Journal: Cell Reports Medicine

Article Title: A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment

doi: 10.1016/j.xcrm.2023.101286

Figure Lengend Snippet:

Article Snippet: The membranes were blocked in 5% non-fat milk and incubated with the following primary antibodies overnight 4°C with constant rotation: β-actin (Sigma-Aldrich, A5441, 1:10000), FLT3 (Cell Signaling Technology, 3462S, 1:1000), phospho-FLT3 (Y589/591) (Cell Signaling Technology, 3464S, 1:1000), AKT (pan) (Cell Signaling Technology, 4685S, 1:1000), phosphor-AKT (S473) (Cell Signaling Technology, 4060S, 1:1000), ERK1/2 (Cell Signaling Technology, 4695S, 1:1000), phosphor-ERK1/2 (T202/Y204) (Cell Signaling Technology, 4370S, 1:1000), STAT5 (Abcam, ab194898, 1:2000), phosphor-STAT5 (Y694) (Abcam, ab32364, 1:1000), p53 [DO-1] (Abcam, ab1101, 1:1000), p53 [E26] (Abcam, ab32389, 1:1000), MYC (Abcam, ab32072, 1:1000), USP10 (Abcam, ab109219, 1:1000).

Techniques: Recombinant, Protease Inhibitor, Microarray, CCK-8 Assay, Inhibition, Negative Control, shRNA, Software